Paper40313573
Nanotechnology-based strategies for vaccine development: accelerating innovation and delivery.
Cheng M and 6 others. Biomater Transl, 2025. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Nanotechnology-based strategies for vaccine development: accelerating innovation and delivery. Papers, record 40313573. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40313573
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nanotechnology-based strategies for vaccine development: accelerating innovation and delivery.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References141
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37573951 | Biosafety of mesoporous silica nanoparticles; towards clinical translation. | Adv Drug Deliv Rev | 2023 | https://conductscience.org/library/papers/37573951 | PubMed |
| 2 | 36602367 | The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate. | J Virol | 2023 | https://conductscience.org/library/papers/36602367 | PubMed |
| 3 | 35683755 | Polymer Nanocomposites: Preparation, Characterisation and Applications. | Nanomaterials (Basel) | 2022 | https://conductscience.org/library/papers/35683755 | PubMed |
| 4 | 30172923 | Use of plant viruses and virus-like particles for the creation of novel vaccines. | Adv Drug Deliv Rev | 2019 | https://conductscience.org/library/papers/30172923 | PubMed |
| 5 | 19782542 | Biodegradable polymeric nanoparticles based drug delivery systems. | Colloids Surf B Biointerfaces | 2010 | https://conductscience.org/library/papers/19782542 | PubMed |
| 6 | 32807876 | Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. | Nat Nanotechnol | 2021 | https://conductscience.org/library/papers/32807876 | PubMed |
| 7 | 36149967 | Self-assembling peptide nanofiber HIV vaccine elicits robust vaccine-induced antibody functions and modulates Fc glycosylation. | Sci Adv | 2022 | https://conductscience.org/library/papers/36149967 | PubMed |
| 8 | 33277608 | Engineering precision nanoparticles for drug delivery. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33277608 | PubMed |
| 9 | 23067445 | Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering. | Vaccine | 2012 | https://conductscience.org/library/papers/23067445 | PubMed |
| 10 | 33360074 | Polymeric nanoparticle vaccines to combat emerging and pandemic threats. | Biomaterials | 2021 | https://conductscience.org/library/papers/33360074 | PubMed |
| 11 | 36423041 | Nanoparticle-Based Delivery Systems for Vaccines. | Vaccines (Basel) | 2022 | https://conductscience.org/library/papers/36423041 | PubMed |
| 12 | 33824489 | Emerging concepts in the science of vaccine adjuvants. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33824489 | PubMed |
| 13 | 38213286 | Novel Organoid Culture System for Improved Safety Assessment of Nanomaterials. | Nano Lett | 2024 | https://conductscience.org/library/papers/38213286 | PubMed |
| 14 | 37705787 | Nanoparticle-based delivery systems as emerging therapy in retinoblastoma: recent advances, challenges and prospects. | Nanoscale Adv | 2023 | https://conductscience.org/library/papers/37705787 | PubMed |
| 15 | 25557605 | Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. | Med Microbiol Immunol | 2015 | https://conductscience.org/library/papers/25557605 | PubMed |
| 16 | 36713441 | Subunit vaccines for Acinetobacter baumannii. | Front Immunol | 2022 | https://conductscience.org/library/papers/36713441 | PubMed |
| 17 | 11584378 | Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. | Hepatology | 2001 | https://conductscience.org/library/papers/11584378 | PubMed |
| 18 | 29801750 | Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. | Semin Immunol | 2018 | https://conductscience.org/library/papers/29801750 | PubMed |
| 19 | 22051890 | Vaccines for the twenty-first century society. | Nat Rev Immunol | 2011 | https://conductscience.org/library/papers/22051890 | PubMed |
| 20 | 30733717 | Nanoparticle-Based Vaccines Against Respiratory Viruses. | Front Immunol | 2019 | https://conductscience.org/library/papers/30733717 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42883287 | Evaluation of the Adjuvant Activity of Herniaria glabra Saponin-Based Nanoadjuvants. | Molecules | 2026 | https://conductscience.org/library/papers/42883287 | PubMed |
| 42760964 | Transforming therapeutics through biomaterials: A comprehensive insight into biomaterials' role in effective drug delivery and healthcare advancement. | Biomater Transl | 2026 | https://conductscience.org/library/papers/42760964 | PubMed |
| 42513179 | Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures. | Molecules | 2026 | https://conductscience.org/library/papers/42513179 | PubMed |
| 42405958 | Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology. | Hum Vaccin Immunother | 2026 | https://conductscience.org/library/papers/42405958 | PubMed |
| 42188374 | Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles. | J Funct Biomater | 2026 | https://conductscience.org/library/papers/42188374 | PubMed |
| 41727253 | Modern plant stress adaptation: integrating defense, nanotechnology and genetics. | 3 Biotech | 2026 | https://conductscience.org/library/papers/41727253 | PubMed |
| 41600930 | Engineering Enhanced Immunogenicity of Surface-Displayed Immunogens in a Killed Whole-Cell Genome-Reduced Bacterial Vaccine Platform Using Class I Viral Fusion Peptides. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/41600930 | PubMed |
| 41012106 | Nanovaccines: Innovative Advances from Design Strategies to Clinical Translation. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/41012106 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40313573
GET https://conductscience.org/api/papers/v1/40313573/references?page=2